VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Sunday, January 11, 2026
Stock Comparison
Eli Lilly and Company vs REA Group Ltd
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Eli Lilly and Company
LLY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Eli Lilly and Company's moat claims, evidence, and risks.
View LLY analysisREA Group Ltd
REA · ASX
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into REA Group Ltd's moat claims, evidence, and risks.
View REA analysisComparison highlights
- Moat score gap: REA Group Ltd leads (91 / 100 vs 82 / 100 for Eli Lilly and Company).
- Segment focus: Eli Lilly and Company has 5 segments (65.5% in Cardiometabolic Health); REA Group Ltd has 3 segments (87.5% in Australia - Property & Online Advertising).
- Primary market structure: Oligopoly vs Duopoly. Pricing power: Strong vs Strong.
- Moat breadth: Eli Lilly and Company has 5 moat types across 3 domains; REA Group Ltd has 6 across 3.
Primary market context
Eli Lilly and Company
Cardiometabolic Health
Cardiometabolic pharmaceuticals (diabetes, obesity, and related metabolic diseases)
Global (with U.S. as the largest market)
Patients via prescribers and payers (commercial/government)
Branded drug developer/manufacturer
65.5%
REA Group Ltd
Australia - Property & Online Advertising
Australian online property classifieds & digital real estate advertising (residential + commercial listings)
Australia
Real estate agents/agencies and developers (advertisers) + property seekers (consumers)
Marketplace operator / media & advertising platform
87.5%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Eli Lilly and Company strengths
REA Group Ltd strengths
Segment mix
Eli Lilly and Company segments
Full profile >Cardiometabolic Health
Oligopoly
Oncology
Competitive
Immunology
Oligopoly
Neuroscience
Competitive
Other
Competitive
REA Group Ltd segments
Full profile >Australia - Property & Online Advertising
Duopoly
Australia - Financial Services
Competitive
India - Online Property Classifieds
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.